TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Laurus Labs Ltd.

LAURUSLABS on NSE · 19 Nov 2026

NIFTY 500 F&O

2,306.00 ▼ -0.71 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance

Filings

34 filings of LAURUSLABS since January 2025.

presentation 10, transcript 8, board outcome 8, results 4, credit rating 2, dividend 1

FiledTypeSubject
03 Nov 2026transcript
Acquisition, Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Transcript
AI summary

Laurus Labs filed the transcript of its Q2 FY27 results conference call hosted on October 29, 2026.

Management reported Q2 total income from operations of INR2,206 crores (highest ever for a quarter), EBITDA of INR762 crores (34.5% margin) and profit after tax of INR441 crores; H1 total income was INR4,233 crores (up 31%), H1 PAT INR809 crores.

Small molecule CDMO Q2 sales were INR875 crores (up 86%); affordable medicines Q2 revenue was INR1,302 crores (up 15% year-on-year).

Management said the first peptide commercial-scale block was commissioned, with commercial revenues expected around 2029, and it announced acquisitions of a 60% stake in Galenvs Sciences (Canada) and majority stake in SI & C Resins.

Management reported Q2 capex of about INR470 crores, H1 capex of INR864 crores, net debt of INR2,466 crores and debt-to-EBITDA of about 1.02.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Oct 2026presentation
Acquisition, Capex, Results
Laurus Labs Limited has informed the Exchange about Investor Presentation
AI summary

Laurus Labs filed its investor/analyst presentation on its standalone and consolidated results for Q2 and H1 FY2027 (quarter and half-year ended September 30, 2026), for a call on October 29, 2026 at 5:00 p.m. IST.

H1 revenue was ₹4,233 Cr, up 31%, with EBITDA of ₹1,406 Cr at a 33.2% margin (up 7.8 percentage points) and gross margin of 62.9% (up over 3.3 percentage points), per management.

Management said CAPEX reached 20% of revenue, reflecting sustained investment in the manufacturing network and niche capabilities.

Management announced a definitive agreement to acquire a 60% stake in Galenvs, an oligonucleotide and precision magnetic nanoparticles company, and a proposed acquisition of a 52% stake in SI&C Resins, a peptide-resin technology company.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Oct 2026board outcome
Dividend / buy-back, Management change, Results
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Board of Laurus Labs approved unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2026, with Limited Review Reports from Deloitte Haskins & Sells LLP.

Consolidated revenue from operations for the quarter ended September 30, 2026 was Rs 2,206.37 crore, against Rs 2,026.31 crore for the quarter ended June 30, 2026; consolidated net profit after tax for the quarter was Rs 436.19 crore (Rs 362.07 crore in the prior quarter), as printed in the statement.

Board approved an interim dividend of Re. 1.00 per equity share (50% on face value of Rs 2) for FY 2026-27, with record date November 6, 2026 and payment on or after November 19, 2026.

Board approved appointment of Mr. Kundan Kumar Jha as Joint Company Secretary, a Key Managerial Personnel, effective November 1, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 Sep 2026presentation
Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Investor Presentation
AI summary

Laurus Labs filed its September 2026 investor presentation with BSE and NSE, also uploaded to the company website.

FY26 revenue was ₹6,813 Cr (up 23% CAGR over FY20-26); FY26 EBITDA was ₹1,826 Cr (up 64%) with EBITDA margin of 26.8%; net debt/EBITDA was 1.3x.

Management said it is guiding for EBITDA margin above 30% from FY27 onwards.

Management said it has invested over ₹3,000 Cr of ~₹4,300 Cr proposed capex, with 85% growth capex; Q1 FY27 capex was ₹394 Cr (19% of revenue).

The presentation reports 0 critical findings across 1,425+ quality audits and inspections, and 15 manufacturing sites and 6 R&D centres.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jul 2026transcript
Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Transcript
AI summary

Laurus Labs filed the transcript of its Q1 FY27 earnings conference call hosted on July 24, 2026.

Management said revenue from operations was INR2,026 crores, up 29% year-on-year, with gross margin at 62.7% and EBITDA of INR644 crores (31.8% margin); profit after tax was about INR368 crores.

CDMO small molecule sales were INR835 crores (up 69%), with about 55% from commercial supplies; Affordable Medicines revenue was INR1,156 crores (up 10%).

Management said capex for the quarter was about INR394 crores, net debt INR2,656 crores and debt-to-EBITDA about 1.28; FY27 capex guidance was raised to INR3,000 crores for FY27 and FY28, with possibly more.

Management also said R&D spend was 5.8% of revenue and that no customer advances were received in the quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jul 2026presentation
Capex, Results
Laurus Labs Limited has informed the Exchange about Presentation
AI summary

Investor/analyst presentation on the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1 FY2027), for the call held July 24, 2026 at 5:00 p.m. IST.

Management stated revenue of ₹2,026 Cr, up 29%, with strong growth in CDMO revenue from commercial project supplies and steady momentum in the Affordable Medicines segment.

EBITDA was ₹644 Cr with a margin of 31.8%, up 7.0 percentage points, attributed to higher CDMO revenue and operating leverage.

Gross margin expanded by over 3.3 percentage points to 62.7% on a healthier business segment mix.

Management said capex was ₹394 Cr (19% of revenue) in Q1, and cumulative FY22-27 capex is ₹4,700+ Cr (16% of revenue), with over 85% of it growth capex.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jul 2026board outcome
Results
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Board of Laurus Labs approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 at a meeting held July 24, 2026; limited review reports from Deloitte Haskins & Sells LLP are annexed.

Consolidated total income for the quarter was Rs 2,035.49 crore (revenue from operations Rs 2,026.31 crore), against Rs 1,569.57 crore revenue in the quarter ended June 30, 2025 per the comparative column.

Consolidated profit before tax was Rs 481.36 crore and net profit after taxes and share of associates and JV was Rs 361.99 crore plus 0.08 crore share from associates, giving profit attributable to equity holders of Rs 359.86 crore.

Consolidated basic EPS was Rs 6.80 (diluted Rs 6.81), on paid-up equity share capital of Rs 107.97 crore (face value Rs 2 each).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Jul 2026credit rating
Rating
Laurus Labs Limited has informed the Exchange about Credit Rating
AI summary

Laurus Labs Limited received the final credit rating letter from CARE Ratings Ltd. on July 03, 2026.

Long-term bank facilities rated CARE AA; Stable, reaffirmed.

Long-term/short-term bank facilities rated CARE AA; Stable / CARE A1+, reaffirmed.

Short-term bank facilities rated CARE A1+, reaffirmed.

The agency's reaffirmation reflects the company's sustained improvement in performance in FY26, with growth in total operating income, uptick in profitability margins and strengthening of debt coverage indicators.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 May 2026transcript
Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Transcript
AI summary

Laurus Labs filed the transcript of its Q4 FY26 results conference call, hosted on April 30, 2026.

Management said FY26 revenue was INR6,813 crores (up 23%), with EBITDA of INR1,826 crores at a 26.8% margin and profit after tax of INR889 crores (up 148%).

Management said Q4 revenue was INR1,812 crores (up 5%) and Q4 EBITDA margin was 28.9%; FY26 capex was about INR1,070 crores and net debt was INR2,285 crores (debt/EBITDA 1.25).

Management said it expects operating leverage to contribute next year and that it has no supply disruptions in the quarter and expects none until end of June.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Apr 2026presentation
Capex, Dividend / buy-back, Results
Laurus Labs Limited has informed the Exchange about Investor Presentation
AI summary

Investor/analyst presentation on Laurus Labs' standalone and consolidated results for the quarter and year ended March 31, 2026, for the call held April 30, 2026 at 5:00 p.m. IST.

FY26 revenues were ₹6,813 Cr (+23%), gross margin 60.4% (+5%), EBITDA ₹1,826 Cr with margin 26.8% (+6.7%), and capex ₹1,070 Cr (16% of sales).

Q4 FY26 revenues were ₹1,812 Cr (+5%) and EBITDA ₹523 Cr with margin 28.9% (+1.6%).

Management stated net debt/EBITDA of -1.0x, a ₹3,000 Cr capex plan for ongoing growth projects, and a total dividend payout of ₹631 Cr to date.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Apr 2026board outcome
Dividend / buy-back, Results
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Board approved audited consolidated and standalone results for FY ended March 31, 2026 and reviewed results for quarter ended March 31, 2026, with Unmodified Opinion from statutory auditors (Deloitte Haskins & Sells LLP).

Consolidated FY2025-26 total income was Rs 6,867.85 crore versus Rs 5,629.06 crore in FY2024-25; consolidated net profit after tax attributable to equity holders was Rs 888.79 crore (FY2024-25: Rs 358.32 crore).

Consolidated revenue from operations for the quarter ended March 31, 2026 was Rs 1,811.57 crore; net profit attributable to equity holders was Rs 279.14 crore.

Board approved a 2nd interim dividend of Rs 1.20 per equity share (60%) of Rs 2 face value for FY2025-26, with record date May 08, 2026 and payment on or after May 20, 2026.

Board approved convening the 21st AGM on July 02, 2026 via video conferencing, with June 25, 2026 as the e-voting cut-off date.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Apr 2026results
Legal, Results
The Exchange had sought clarification from Laurus Labs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company wa
AI summary

Laurus Labs responded to NSE clarification (dated January 12, 2026) on deficiencies in its October 23, 2025 financial results filing.

The company attributed the lapses to a NEAPS portal technical glitch: the PDF was not converted to machine-readable format, and submission took a few minutes longer than the prescribed time limit.

Half-yearly figures were inadvertently selected in the XBRL filing, and a revised and correct XBRL was filed on January 23, 2026.

The filing also includes the October 23, 2025 outcome of board meeting approving unaudited standalone and consolidated results for the quarter and half-year ended September 30, 2025, with limited review reports from Deloitte Haskins & Sells LLP.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Jan 2026transcript
Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Transcript
AI summary

Laurus Labs filed the transcript of its Q3 FY26 results conference call, hosted on January 23, 2026.

Management reported Q3 total income from operations of Rs. 1,778 crore (26% growth), gross margin of 60.9% and EBITDA margin of 27%; 9-month income of Rs. 5,001 crore (30% growth) and 9-month PAT of Rs. 610 crore.

Generic division Q3 revenue was Rs. 1,327 crore (37% growth); Q3 small molecule CDMO sales were Rs. 408 crore and Bio division Q3 sales were Rs. 43 crore.

Management said overall capex for the current year will be about Rs. 1,000 crore and is expected to be over Rs. 1,000 crore next year; ROCE was 18.5%, and it did not commit to reaching 25% ROCE within 12 months.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 Jan 2026presentation
Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Investor Presentation
AI summary

Laurus Labs filed the investor/analyst presentation for its unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, for a call on January 23, 2026 at 5:00 PM IST.

9M FY2026 revenue was ₹5,001 Cr, up 30%, led by the CDMO division with a robust Generics division.

9M EBITDA was ₹1,303 Cr at a margin of 26.1%, up 9.4% points, and gross margin rose over 4.3% points to 60.1%.

9M capex was ₹735 Cr, about 15% of revenue; management said the company is well on track to deliver healthy operational growth in FY2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 Jan 2026board outcome
Legal, Results
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Laurus Labs Limited's board on January 23, 2026 approved unaudited consolidated financial results for the quarter and nine months ended December 31, 2025, with a limited review report from Deloitte Haskins & Sells LLP.

Consolidated total income for the quarter ended December 31, 2025 was Rs 1,784.05 crore, against Rs 1,680.43 crore for the quarter ended September 30, 2025; consolidated net profit after tax and share of associates/JV was Rs 251.88 crore...

The board also noted a change in the address of the Corporate Office to Plot No. 103, Road No. 1, Jubilee Hills, Hyderabad – 500033, Telangana.

The board meeting commenced at 2.00 p.m. and concluded at 2.40 p.m.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Jan 2026resultsThe Exchange has sought clarification from Laurus Labs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is
28 Oct 2025transcript
Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Transcript
AI summary

Laurus Labs filed the transcript of its Q2 FY26 results conference call, hosted on October 23, 2025.

Management reported Q2 revenue of INR1,653 crores (up 35%), H1 total income of INR3,223 crores (up 33%), Q2 EBITDA of INR429 crores at a 26% margin, and Q2 profit after tax of INR195 crores.

CDMO Q2 sales were INR471 crores and generics Q2 sales were INR1,135 crores (up 28%), per management.

Management said ARV sales are expected to be around INR2,500 crores for the year, plus or minus a couple of hundred crores, and total capex for the current year is expected to be closer to INR1,000 crores.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 Oct 2025presentation
Acquisition, Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Investor Presentation
AI summary

Laurus Labs filed the investor/analyst presentation on its standalone and consolidated results for the quarter and half-year ended September 30, 2025 (Q2 & H1 FY2026), for a call held October 23, 2025 at 5:00 p.m. IST.

H1 revenue was ₹3,223 Cr, up 33%, per the presentation; EBITDA was ₹818 Cr at a 25.4% margin, up 10.8 percentage points.

Gross margin rose over 4.5 percentage points to 59.6% on a healthier business mix, per the presentation.

Management said capex was 15% of sales and it is continuing investment in manufacturing network expansion.

Management said it proposes to invest over US$600 million in pharma manufacturing and R&D over the next several years, after the Andhra Pradesh government allotted 532 acres in Vizag on July 27, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 Oct 2025board outcome
Dividend / buy-back, Results
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, with Limited Review Reports from Deloitte Haskins & Sells LLP annexed (figures are in the annexures, not in the pages provided).

Board approved an interim dividend of Rs.0.80 per equity share (40%) of face value Rs.2 each for FY 2025-26.

Record date for the interim dividend is October 31, 2025; payment will be made on or after November 12, 2025.

The board meeting commenced at 2:00 p.m. and concluded at 2:55 p.m. on October 23, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Sep 2025presentation
Capex, Results
Laurus Labs Limited has informed the Exchange about Investor Presentation
AI summary

Laurus Labs filed its September 2025 investor/analyst presentation with BSE and NSE on September 12, 2025, also uploaded to the company website.

The presentation shows FY25 revenues of ₹5,554 Cr and a 20.1% EBITDA margin.

Business split: CDMO 28% and Generics (FDF and API) 72% of revenues.

Operations cover about 7,900 KL of reactor volume across multiple Vizag sites, 240 KL of fermentation capacity, and over 1,400 scientists.

R&D: more than 75 R&D projects supported in FY25, with a 40% increase in Bio-catalysis projects and a 30% increase in continuous flow reaction projects.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 Aug 2025scheme
Acquisition, Legal
Laurus Labs Limited has informed the Exchange about Approval of Scheme of Arrangement
AI summary

Board of Laurus Labs approved, subject to requisite approvals, a Composite Scheme of Arrangement under Sections 230-232 of the Companies Act, 2013, on August 21, 2025.

The scheme demerges Unit-1 of wholly owned subsidiary Laurus Synthesis Private Limited into wholly owned subsidiary Sriam Labs Private Limited, and amalgamates the remaining business of Laurus Synthesis into Laurus Labs Limited, dissolving that subsidiary without winding up.

Appointed date is April 1, 2026, or another date approved by NCLT or other authority.

Net worth as on March 31, 2025 (Rs. crore): Laurus Labs 4,563.95; Laurus Synthesis 119.60; Sriam Labs 59.39. Turnover: Laurus Labs 5,216.99; Laurus Synthesis 236.95; Sriam Labs 62.50.

Sriam Labs will issue 27 equity shares of Rs.10 each for every 1 share of Rs.10 held by Laurus Labs in Laurus Synthesis for Unit-1; no shares will be issued for the amalgamation, and Laurus Labs' shareholding will not change.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Jul 2025transcript
Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Transcript
AI summary

Laurus Labs filed the transcript of its Q1 FY26 earnings conference call, hosted on July 25, 2025.

Management said Q1 revenue was INR1,570 crores (up 31% year-on-year), with CDMO sales of INR493 crores and Generics sales of INR1,048 crores (up 12%); Laurus Bio sales were INR29 crores, flat year-on-year.

CFO V.V. Ravi Kumar said gross margin was 59%, EBITDA was INR389 crores at a 25% margin, profit after tax was INR163 crores, and net debt was INR2,388 crores (debt to EBITDA 1.8).

CEO Dr. Satyanarayana Chava said gross margins are expected to stay between 55% and 60% in coming quarters and that CDMO could reach about 50% of revenue in the near to medium term, described as a guesstimate.

Management said three capacity expansions were announced in the quarter (Vizag microbial fermentation Phase 1, Shameerpet gene therapy and ADC GMP facility, and a Krka joint venture formulation facility in Hyderabad), and that Q1 capex was about INR265 crores.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Jul 2025presentation
Capex, Results
Laurus Labs Limited has informed the Exchange about Investor Presentation
AI summary

Laurus Labs filed its investor/analyst presentation on the standalone and consolidated unaudited results for the quarter ended June 30, 2025 (Q1 FY2026), for a call held on July 25, 2025 at 5:00 p.m. IST.

Management reported revenues of ₹1,570 Cr, up 31%, and EBITDA of ₹389 Cr at a margin of 24.8%, improved by 10.5 percentage points, attributed to CDMO ramp-up and operating leverage.

Gross margin was 59.4% on positive product mix.

Q1 capex was ₹265 Cr, or 17% of revenues; total capex for FY22-26 is about ₹3,400 Cr.

Management said asset turnover has recovered since mid-FY25 and is projected to return to normalised levels over the next two years.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Jul 2025board outcome
Results
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Laurus Labs Limited's board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 at a meeting on July 25, 2025; Deloitte Haskins & Sells LLP issued an unmodified limited review conclusion.

Consolidated revenue from operations for Q1 FY26 (quarter ended June 30, 2025) was Rs 1,569.57 crores, versus Rs 1,194.91 crores in the quarter ended June 30, 2024 and Rs 1,720.30 crores in the quarter ended March 31, 2025.

Consolidated total income was Rs 1,580.00 crores and profit before tax was Rs 224.22 crores; net profit after tax was Rs 161.68 crores (before share of associates and joint venture loss).

Consolidated net profit attributable to equity holders was Rs 162.31 crores (basic EPS Rs 3.02 for the quarter per the printed table; year-ended FY25 total comprehensive income was Rs 354.67 crores).

The company invested Rs 40 crores in subsidiary Laurus Bio Private Limited during the quarter, and allotted 572,408 equity shares under its Employee Stock Option Scheme.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Jul 2025credit rating
Rating
Laurus Labs Limited has informed the Exchange about Credit Rating
AI summary

Laurus Labs Limited received the final credit rating letter from CARE Ratings Ltd. on July 01, 2025.

Long-term bank facilities rated CARE AA; Stable, reaffirmed, with outlook revised from Negative to Stable.

Short-term bank facilities rated CARE A1+, reaffirmed.

CARE attributed the long-term outlook revision to improved performance in FY25, with growth in total operating income, higher profitability margins and stronger debt coverage indicators.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 May 2025board outcome
Legal
Laurus Labs Limited has informed the Exchange regarding Convening of 20th Annual General Meeting ('AGM') of the Company on Thursday, June 26, 2025 through Video Conferencing/Other Audio Visual Means
AI summary

Outcome of the Board Meeting held on May 15, 2025, which ran from 2.00 p.m. to 2.30 p.m.

The Board approved the notice convening the 20th Annual General Meeting on Thursday, June 26, 2025, through video conferencing / other audio visual means.

June 19, 2025 is fixed as the cut-off date for e-voting in connection with the 20th AGM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Apr 2025transcript
Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Transcript
AI summary

Laurus Labs filed the transcript of its Q4 FY25 results conference call hosted on April 24, 2025.

Management reported FY25 revenue of INR5,554 crores (up 10%), with Q4 revenue of INR1,720 crores (up 19% year on year), gross margin of 55.4% for the full year, and full-year EBITDA margin of 20.1%.

Full-year profit after tax was INR258 crores (growth of 122%), and net debt was INR2,594 crores with net debt to EBITDA of 2.3 versus 3.1 a year earlier.

Management said FY25 capex was INR659 crores and that operating margin is expected to improve in FY26 from better asset utilization and product mix.

Management said ImmunoACT's NexCAR19 manufacturing capacity expansion is due to be ready for operations by September 2025, and the company plans to break ground for a commercial-scale fermentation facility in Vizag by June 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Apr 2025board outcome
Dividend / buy-back, Results
Laurus Labs Limited has informed the Exchange regarding Outcome of Board Meeting held on April 24, 2025.
AI summary

Board outcome dated April 24, 2025: approved audited standalone and consolidated results for FY ended March 31, 2025 and limited reviewed results for quarter ended March 31, 2025; auditor Deloitte Haskins & Sells LLP issued unmodified opinion.

Consolidated FY2024-25 revenue from operations Rs 5,553.96 crore (vs Rs 5,040.83 crore in FY2023-24); consolidated net profit after taxes and share of associates Rs 354.69 crore (vs Rs 159.40 crore in FY2023-24) per the printed table.

Consolidated basic EPS for the year Rs 6.65 (vs Rs 2.98 in the prior year), face value Rs 2 per share.

Board approved 2nd interim dividend of Rs 0.80 per equity share (40%) of face value Rs 2 for FY2024-25, with record date May 9, 2025 and payment on or after May 20, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Apr 2025presentation
Capex, Guidance, Legal, Results
Laurus Labs Limited has informed the Exchange about Investor Presentation
AI summary

Laurus Labs filed an investor/analyst presentation on its standalone and consolidated financial results for the quarter and year ended March 31, 2025, for an analyst call held on April 24, 2025 at 5:00 p.m. IST.

FY 2025 consolidated revenue was ₹5,554 Cr, up 10%; EBITDA was ₹1,115 Cr with a 20.1% margin (up 4.2 pp); capex was ₹659 Cr, 12% of sales.

FY 2025 CDMO/Custom segment revenue was ₹1,720 Cr, up 19%, with EBITDA of ₹477 Cr and a 27.7% margin (up 9.7 pp), as presented in the deck.

Net debt/EBITDA was -0.6x, and net debt stood at ₹2,594 Cr; management said the company expanded gross and EBITDA margins and focused capital deployment on high-return CMO/CDMO segments.

Management described the small-molecule CDMO market as structurally growing, while citing tariff uncertainty and US Inflation Reduction Act pricing pressure as short-term noise.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Apr 2025dividend
Dividend / buy-back, Results
Laurus Labs Limited has informed the Exchange that Board of Directors at its meeting held on April 24, 2025, declared Interim Dividend of 0.80 per equity share.
AI summary

Board of Laurus Labs approved audited standalone and consolidated results for the year ended March 31, 2025 and reviewed results for the quarter ended March 31, 2025, with unmodified audit opinion from Deloitte Haskins & Sells LLP.

Consolidated total income for FY2025 was Rs 5,629.06 crore (Rs 5,067.17 crore in FY2024), and consolidated net profit after taxes and share of associates was Rs 354.69 crore for the year (Rs 159.40 crore in FY2024), as printed in the filing.

Board approved a 2nd interim dividend of Rs 0.80 per equity share of Rs 2 each (40%) for FY 2024-25.

Record date for the dividend is May 09, 2025, and payment will be made on or after May 20, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Jan 2025transcript
Acquisition, Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Transcript
AI summary

Laurus Labs filed the transcript of its Q3 FY25 earnings conference call, hosted on January 24, 2025.

Management reported Q3 revenue of INR1,415 crores, up 18% year-on-year, and 9-month total income from operations of about INR3,834 crores, up 6%.

Q3 EBITDA was INR285 crores at a 20.1% margin; Q3 profit after tax was INR92 crores; net debt stood at INR2,766 crores with debt to EBITDA of about 3.1.

CDMO sales were close to INR400 crores in Q3, the highest quarterly level in eight quarters, and 33% growth on a 9-month basis, per management.

Management said it remains committed to its 2025 growth outlook for CDMO, expects API growth to return next year, and said it is not giving a quantum for FY26 CDMO revenue; it expects an EBITDA margin for the full year closer to 20%.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jan 2025results
Results
Please see annexed enclosure.
AI summary

Laurus Labs Limited filed its integrated financial filing (financial results) for the quarter and nine months ended December 31, 2024, approved by the Board on January 24, 2025.

Consolidated revenue from operations for Q3 FY25 (quarter ended Dec 31, 2024) was Rs 1,415.05 crore, versus Rs 1,223.70 crore in the previous quarter and Rs 1,194.92 crore in the year-ago quarter.

Consolidated net profit after tax and share of associates/JV for the quarter was Rs 92.94 crore, versus Rs 19.95 crore in the previous quarter and Rs 23.34 crore a year ago.

For the nine months ended Dec 31, 2024, revenue from operations was Rs 3,833.66 crore (Rs 3,601.16 crore a year ago) and net profit was Rs 125.57 crore (Rs 87.25 crore a year ago).

Basic EPS for the quarter was Rs 1.71 per share (face value Rs 2).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jan 2025presentation
Acquisition, Capex, Guidance, Results
Laurus Labs Limited has informed the Exchange about Investor Presentation
AI summary

Laurus Labs filed its investor/analyst presentation on the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2024 (call held January 24, 2025, 5.00 PM IST).

Management reported revenues of ₹ 3,834 Cr in 9M FY25, a 6% growth, and EBITDA of ₹ 638 Cr at a 16.6% margin; gross margin was 55.8%.

Management said performance remains on track for full-year growth, with Q4 revenue acceleration from planned project deliveries, and the FY 2025 outlook is retained.

Subsidiary Laurus Bio signed an agreement on 6 Dec 2024 to raise ₹ 120 Cr from Eight Roads Ventures and F-Prime Capital, with Laurus Labs co-investing an additional ₹ 40 Cr; post-deal stakes would be 75% (Laurus Labs) and 14% (Eight Roads).

9M CAPEX was ₹ 448 Cr, 12% of revenues; management described it as directed to high-return API/CDMO projects.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jan 2025results
Results
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
AI summary

Laurus Labs Limited filed its unaudited consolidated financial results for the quarter and nine months ended December 31, 2024, approved by the Board on January 24, 2025, with a Limited Review Report from Deloitte Haskins & Sells LLP.

Consolidated revenue from operations for Q3 FY25 (quarter ended Dec 31, 2024) was Rs 1,415.05 crore, against Rs 1,194.92 crore in the year-ago quarter; net profit after tax and share of associates/JV was Rs 92.94 crore, against Rs 23.34 crore a year earlier.

For the nine months ended Dec 31, 2024, revenue from operations was Rs 3,833.66 crore (Rs 3,601.16 crore a year earlier) and net profit was Rs 125.57 crore (Rs 87.25 crore a year earlier).

Basic earnings per share for the quarter was Rs 1.71 (Rs 0.43 a year earlier).

During the quarter, Laurus Bio Private Limited received Rs 120 crore from investors Eight Roads Ventures and F-Prime Capital, and the company contributed Rs 45 crore to joint venture KRKA Pharma Private Limited.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in